Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven M Rowe

Showing results (91-100 of 269) with videos related to

Pageof 27
Sort By:
The Lancet. Respiratory Medicine|June 15, 2016
Pulmonary artery enlargement and cystic fibrosis pulmonary exacerbations: a cohort studyJ Michael Wells, Roopan F Farris, Taylor A Gosdin, et al.
The European Respiratory Journal|February 4, 2022
Static mucus impairs bacterial clearance and allows chronic infection with <i>Pseudomonas aeruginosa</i> in the cystic fibrosis ratAlexander G Henderson, Joy M Davis, Johnathan D Keith, et al.
Pediatric Pulmonology|August 4, 2022
Plasma and cellular ivacaftor concentrations in patients with cystic fibrosisJennifer S Guimbellot, Kevin J Ryan, Justin D Anderson, et al.
The Lancet. Respiratory Medicine|June 14, 2015
Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trialRichard B Moss, Patrick A Flume, J Stuart Elborn, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 12, 2020
Variable cellular ivacaftor concentrations in people with cystic fibrosis on modulator therapyJennifer S Guimbellot, Kevin J Ryan, Justin D Anderson, et al.
World Journal of Otorhinolaryngology - Head and Neck Surgery|December 6, 2017
Protective and antifungal properties of Nanodisk-Amphotericin B over commercially available Amphotericin BDo-Yeon Cho, Kyle J Hoffman, Gobind S Gill, et al.
The Pediatric Infectious Disease Journal|October 1, 2019
Area Deprivation as a Risk Factor for Methicillin-resistant Staphylococcus aureus Infection in Pediatric Cystic FibrosisGabriela R Oates, William T Harris, Steven M Rowe, et al.
Annals of the American Thoracic Society|November 30, 2016
Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTRSteven M Rowe, Susanna A McColley, Ernst Rietschel, et al.
The Journal of Clinical Investigation|September 5, 2024
Elexacaftor/tezacaftor/ivacaftor's effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatmentSarah J Morgan, Ellis Coulter, Hannah L Betts, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 12, 2021
Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC studyEdith T Zemanick, Michael W Konstan, Donald R VanDevanter, et al.
Pageof 27

Showing results (91-100 of 269) with videos related to

Sort By:
Pageof 27
The Lancet. Respiratory Medicine|June 15, 2016
Pulmonary artery enlargement and cystic fibrosis pulmonary exacerbations: a cohort studyJ Michael Wells, Roopan F Farris, Taylor A Gosdin, et al.
The European Respiratory Journal|February 4, 2022
Static mucus impairs bacterial clearance and allows chronic infection with <i>Pseudomonas aeruginosa</i> in the cystic fibrosis ratAlexander G Henderson, Joy M Davis, Johnathan D Keith, et al.
Pediatric Pulmonology|August 4, 2022
Plasma and cellular ivacaftor concentrations in patients with cystic fibrosisJennifer S Guimbellot, Kevin J Ryan, Justin D Anderson, et al.
The Lancet. Respiratory Medicine|June 14, 2015
Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trialRichard B Moss, Patrick A Flume, J Stuart Elborn, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 12, 2020
Variable cellular ivacaftor concentrations in people with cystic fibrosis on modulator therapyJennifer S Guimbellot, Kevin J Ryan, Justin D Anderson, et al.
World Journal of Otorhinolaryngology - Head and Neck Surgery|December 6, 2017
Protective and antifungal properties of Nanodisk-Amphotericin B over commercially available Amphotericin BDo-Yeon Cho, Kyle J Hoffman, Gobind S Gill, et al.
The Pediatric Infectious Disease Journal|October 1, 2019
Area Deprivation as a Risk Factor for Methicillin-resistant Staphylococcus aureus Infection in Pediatric Cystic FibrosisGabriela R Oates, William T Harris, Steven M Rowe, et al.
Annals of the American Thoracic Society|November 30, 2016
Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTRSteven M Rowe, Susanna A McColley, Ernst Rietschel, et al.
The Journal of Clinical Investigation|September 5, 2024
Elexacaftor/tezacaftor/ivacaftor's effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatmentSarah J Morgan, Ellis Coulter, Hannah L Betts, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 12, 2021
Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC studyEdith T Zemanick, Michael W Konstan, Donald R VanDevanter, et al.
Pageof 27